Novo Nordisk, the maker of blockbuster weight reduction drugs Wegovy/Ozempic (semaglutide) just added another feather to its cap with strong positive results from its kidney outcomes trial FLOW, which was stopped early due to promising interim results
‘The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24% for people treated with semaglutide 1.0 mg compared to placebo’
Naturally, this will enable Novo to file for a label extension and reinforce its leadership in Diabetes/Obesity Care
Martin Holst Lange, executive vice president for Development at Novo Nordisk said: “Approximately 40% of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.”